お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
497068

市場アクセスにおける課題:HIV (米国)

Market Access Impact: HIV (US) 2018

出版日: | 発行: FirstWord | ページ情報: 英文 | 納期: 即日から翌営業日

価格
詳細については [見積・お問合せ] ボタンよりお問い合わせ下さい。
市場アクセスにおける課題:HIV (米国)
出版日: 2018年03月01日
発行: FirstWord
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、米国の感染症専門医100名を対象にHIV治療薬の処方動向を調査し、市場アクセスにおける各種障壁と処方への影響、主要10ブランド薬の処方に関する比較分析・個別分析を行っています。

調査課題

  • 各種障壁の市場アクセスへの影響
    • 医師がもっとも多く処方するブランドは?
    • 市場の障壁は処方の意思決定にどのように影響しているか?
    • 各種障壁に影響力の違いはあるか?
  • 各ブランドへの障壁の影響
    • 各ブランドを処方する医師の数は?処方していないが検討するつもりの数は?
    • 処方しない理由は?その代わりに処方しているものは?
    • 市場シェアを取り合っている競合ブランドは?

調査対象

  • Descovy (エムトリシタビン/テノホビルアラフェナミド:Gilead)
  • Genvoya (コビシスタット/エルビテグラビル/エムトリシタビン/テノホビルアラフェナミド:Gilead)
  • Isentress (ラルテグラビル:Merck & Co.)
  • Prezcobix (ダルナビル/コビシスタット:Janssen Biotech)
  • Prezista (ダルナビル:Janssen Biotech)
  • Reyataz (アタザナビル:BMS)
  • Stribild (コビシスタット/エルビテグラビル/エムトリシタビン/テノホビルジソプロキシルフマル酸塩:Gilead)
  • Triumeq (アバカビル/ドルテグラビル/ラミブジン:ViiV Healthcare)
  • Truvada (エムトリシタビン/テノホビルジソプロキシルフマル酸塩:Gilead)
  • Viread (テノホビルジソプロキシルフマル酸塩:Gilead)
目次

Market barriers affect just over 1 in 10 HIV prescriptions. Is your brand losing out?

In the US, where market barriers affect just over one in 10 HIV prescriptions, the top brand has a significant lead over all other brands. Find out what's driving its share gains, and what your brand can do to level the playing field in Market Access Impact: HIV (US) [2018].

Based on a survey of 100 infectious disease specialists, the report covers 12 major therapies from Gilead, ViiV, Merck & Co., BMS and Janssen Biotech. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect just over one in 10 prescriptions: But is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • Only one brand sees a significant share increase: Four brands gain share thanks to barriers, but the top-gaining brand sees a much bigger bump than the other three.
  • One brand sees a significant loss: This brand loses 2.5% of its market share because of barriers. Why? And can this be prevented?
  • Eliminating barriers would have limited impact at the top and bottom of the table: The leading brand relies on other brands losing out, but removing barriers wouldn't have a massive impact on market share for other brands. What does this mean to the overall makeup of the market?
  • Two brands have a perception problem: Between a quarter and a third of surveyed doctors would not prescribe these brands, leaving other brands to capture market share.

Insight into 12 Major HIV Drugs

  • Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Descovy (emtricitabine/tenofovir alafenamide; Gilead)
  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
  • Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide; Gilead)
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
  • Tivicay (dolutegravir; ViiV Healthcare)
  • Isentress (raltegravir; Merck & Co.)
  • Prezcobix (darunavir/cobicistat; Janssen Biotech)
  • Edurant (rilpivirine; Janssen Biotech)
  • Prezista (darunavir; Janssen Biotech)
  • Reyataz (atazanavir; Bristol-Myers Squibb)
  • Juluca (dolutegravir/rilpivirine,ViiV Healthcare)

Exploring Market Access Barriers

Market Access Impact: HIV (US) explores key issues affecting HIV drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based infectious disease specialists, chosen from the largest community of validated physicians in the world. All respondents have:

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients in total in the last month

We conducted the survey between March 5-12, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

1.What are market barriers?

2.About this report

3.About the survey

4.Brands included in the survey

5.Executive summary

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.